US Broker Ratings

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A 46% Upside Potential Amid Strong Buy Ratings

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) has been capturing the attention of investors with its significant potential upside and unanimous buy ratings from analysts. As a clinical-stage..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: 76.57% Upside Potential and Robust Revenue Growth

Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a promising player in the healthcare sector, has caught the attention of investors with its impressive revenue growth and substantial upside..

Personalis, Inc. (PSNL) Stock Analysis: Exploring a 30.8% Potential Upside in the Healthcare Sector

For investors with a keen eye on the healthcare sector, Personalis, Inc. (NASDAQ: PSNL) presents a compelling opportunity, underscored by a potential upside of 30.8% based..

Semler Scientific (SMLR) Stock Analysis: A Deep Dive into Its 278% Potential Upside

Semler Scientific, Inc. (SMLR), a U.S.-based provider of medical devices, is currently trading at $17.35, presenting a compelling opportunity for investors seeking high growth potential in..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: Uncovering a Potential 131.77% Upside in Biotech Innovation

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a compelling entity in the biotechnology sector, with its focus sharply tuned towards developing revolutionary treatments for both childhood..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A Biotech Innovator with a 13.50% Upside Potential

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is making waves in the biotechnology sector with a promising portfolio of immunology-based therapies. As a clinical-stage biopharmaceutical company, Zenas BioPharma..

Enhabit, Inc. (EHAB) Stock Analysis: Navigating Investment Opportunities in the Healthcare Sector

Enhabit, Inc. (NASDAQ: EHAB), a prominent player in the healthcare sector, is garnering investor attention with its specialized focus on home health and hospice services in..

COMPASS Pathways Plc (CMPS) Stock Analysis: A 145% Upside Potential in the Mental Health Revolution

For investors with a keen eye on the burgeoning healthcare sector, COMPASS Pathways Plc (NASDAQ: CMPS), a trailblazer in mental health treatment innovation, presents a compelling..

Definitive Healthcare Corp. (DH) Investor Outlook: Potential 43% Upside Amid Challenging Metrics

Definitive Healthcare Corp. (NASDAQ: DH) is a notable player in the health information services industry, carving its niche by offering a comprehensive software-as-a-service (SaaS) healthcare commercial..

Sionna Therapeutics, Inc. (SION) Stock Analysis: Exploring Growth Potential with a Robust Pipeline in Cystic Fibrosis Treatment

Sionna Therapeutics, Inc. (SION), a clinical-stage biopharmaceutical company focused on innovative therapies for cystic fibrosis (CF), has garnered significant attention from investors. With a market capitalization..

Cel-Sci Corporation (CVM) Stock Analysis: Is an 808% Potential Upside Realistic?

For investors eyeing the biotechnology sector, Cel-Sci Corporation (CVM) presents a compelling, albeit high-risk, opportunity. With a market capitalization of $37.41 million and a focus on..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Can a 126% Upside Spark Investor Confidence?

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) occupies a unique niche within the healthcare sector as a pioneering biotechnology firm dedicated to developing gene therapies for rare and..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring Its Growth Potential in the Healthcare Diagnostics Sector

Castle Biosciences, Inc. (NASDAQ: CSTL), headquartered in Friendswood, Texas, is a pioneering molecular diagnostics company that has carved a niche in the healthcare sector with its..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Exploring a 61.91% Potential Upside in Biotech

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) stands out in the biotechnology sector, capturing investor interest with a potential upside of 61.91%. As a clinical-stage pharmaceutical company, Amylyx..

AxoGen, Inc. (AXGN) Stock Analysis: Capitalizing on a 23.5% Revenue Growth in the Medical Device Sector

AxoGen, Inc. (NASDAQ: AXGN) is a key player in the healthcare sector, focusing on the development and commercialization of innovative technologies for peripheral nerve regeneration and..

SI-BONE, Inc. (SIBN) Stock Analysis: 27% Potential Upside and Strong Buy Ratings Signal Growth Opportunities

SI-BONE, Inc. (NASDAQ: SIBN), a prominent player in the healthcare sector specializing in medical devices, is drawing investor interest with its innovative solutions addressing musculoskeletal disorders...

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis: Navigating Biotech’s Turbulent Waves with a 52.55% Upside Potential

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a promising name in the biotechnology sector, focusing on therapies for central nervous system disorders. This Boston-based clinical-stage biopharmaceutical..

Geron Corporation (GERN) Stock Analysis: Biotech Pioneer with a Potential Upside of 157.14%

For investors seeking opportunities in the ever-evolving healthcare sector, Geron Corporation (NASDAQ: GERN) presents an intriguing proposition. As a biotechnology company focused on oncology therapeutics, Geron..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Unveiling a 19.95% Potential Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biopharmaceutical company, is attracting attention within the biotechnology sector, primarily due to its innovative pipeline and substantial market potential...

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 64% Potential Upside

In the dynamic world of biotechnology, Trevi Therapeutics, Inc. (NASDAQ: TRVI) is gaining attention from investors with its ambitious clinical trials and promising market outlook. Specializing..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds